Canagliflozin/metformin immediate-release - Janssen

Drug Profile

Canagliflozin/metformin immediate-release - Janssen

Alternative Names: CANA/MET IR FDC; Invokamet; Metformin immediate-release/canagliflozin - Janssen; Metformin immediate-release/canagliflozin - Johnson & Johnson; Vokanamet

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Pharmaceuticals; Janssen Research & Development
  • Class Antihyperglycaemics; Biguanides; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2017 Janssen Research and Development files sNDA to reduce the risk of major adverse cardiovascular events composed of cardiovascular death, myocardial infarction and stroke patients with Type 2 diabetes mellitus in USA
  • 21 Aug 2017 Canagliflozin/metformin immediate release licensed to Mundipharma Medical Company in Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Ireland, Luxembourg, the Netherlands, Poland, Slovakia, Sweden and Switzerland
  • 16 May 2017 The US FDA issues the boxed warning for canagliflozin/metformin immediate-release to include increased risk of leg and foot amputation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top